Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline

被引：166

作者：

Anthony, Kara B. ^{[1
,4
]}

Fishman, Neil O. ^{[1
,4
]}

Linkin, Darren R. ^{[1
,3
,4
,5
]}

Gasink, Leanne B. ^{[1
,4
,5
]}

Edelstein, Paul H. ^{[2
]}

Lautenbach, Ebbing ^{[1
,3
,4
,5
]}

机构：

[1] Univ Penn, Sch Med, Div Infect Dis, Dept Med, Philadelphia, PA 19104 USA

[2] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA

[3] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA

[4] Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA

[5] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2008年 / 46卷 / 04期

关键词：

D O I：

10.1086/526775

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 [免疫学];

摘要：

Eighteen patients received tigecycline as treatment for infection due to multidrug-resistant gram-negative bacilli, including Acinetobacter baumannii and Klebsiella pneumoniae carbapenemase - and extended-spectrum beta-lactamase-producing Enterobacteriaceae. Pretherapy minimum inhibitory concentration values for tigecycline predicted clinical success. Observed evolution of resistance during therapy raises concern about routine use of tigecycline in treatment of such infections when other therapies are available.

引用

页码：567 / 570

页数：4

共 16 条

[1]

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data [J].

Babinchak, T ;

Ellis-Grosse, E ;

Dartois, N ;

Rose, GM ;

Loh, E .

CLINICAL INFECTIOUS DISEASES, 2005, 41 :S354-S367

[2]

Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY:: molecular epidemiology and in vitro activity of polymyxin B and other agents [J].

Bratu, S ;

Tolaney, P ;

Karumudi, U ;

Quale, J ;

Mooty, M ;

Nichani, S ;

Landman, D .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (01) :128-132

[3]

Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae [J].

Daly, Michael W. ;

Riddle, David J. ;

Ledeboer, Nathan A. ;

Dunne, W. Michael ;

Ritchie, David J. .

PHARMACOTHERAPY, 2007, 27 (07) :1052-1057

[4]

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam [J].

Ellis-Grosse, EJ ;

Babinchak, T ;

Dartois, N ;

Rose, G ;

Loh, E .

CLINICAL INFECTIOUS DISEASES, 2005, 41 :S341-S353

[5]

CDC DEFINITIONS FOR NOSOCOMIAL INFECTIONS, 1988 [J].

GARNER, JS ;

JARVIS, WR ;

EMORI, TG ;

HORAN, TC ;

HUGHES, JM .

AMERICAN JOURNAL OF INFECTION CONTROL, 1988, 16 (03) :128-140

[6]

Tigecycline: in-vitro performance as a predictor of clinical efficacy [J].

Hawkey, P. ;

Finch, R. .

CLINICAL MICROBIOLOGY AND INFECTION, 2007, 13 (04) :354-362

[7]

Multidrug-resistant Acinetobacter infections:: An emerging challenge to clinicians [J].

Jain, R ;

Danziger, LH .

ANNALS OF PHARMACOTHERAPY, 2004, 38 (09) :1449-1459

[8]

Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae:: Risk factors for infection and impact of resistance on outcomes [J].

Lautenbach, E ;

Patel, JB ;

Bilker, WB ;

Edelstein, PH ;

Fishman, NO .

CLINICAL INFECTIOUS DISEASES, 2001, 32 (08) :1162-1171

[9]

Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes [J].

Livermore, DM ;

Winstanley, TG ;

Shannon, KP .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 :87-102

[10]

MADISON NJ, 2007, WYETH PHARM

← 1 2 →